Browsing Category
Featured Articles
Cognizant and Gilead Extend Partnership with Five-Year Service Agreement Estimated at $800 Million
Cognizant announced an expansion of its relationship with Gilead Sciences. Gilead is a leading biopharmaceutical company advancing innovative medicines to prevent and treat…
Read More...
Read More...
VANFLYTA First FLT3 Inhibitor Approved in the U.S. Specifically for Patients with Newly Diagnosed…
Daiichi Sankyo announced that VANFLYTA (quizartinib) has been approved by the U.S. Food and Drug Administration (FDA) in combination with standard cytarabine and anthracycline induction…
Read More...
Read More...
Ipsen announces European Commission decision on palovarotene for the treatment of FOP
Ipsen announced that the European Commission has followed guidance provided by the Committee for Medicinal Products for Human Use (CHMP) in May this year, and has not granted marketing…
Read More...
Read More...
FDA Approves Veklury (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment,…
Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) for the use of Veklury (remdesivir) in COVID-19…
Read More...
Read More...
Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV…
Gilead Sciences, Inc. is pleased to announce two public-private partnerships. The first will accelerate the development of an investigational dispersible pediatric formulation…
Read More...
Read More...
FDA approves expanded indication for Novartis Leqvio (inclisiran) to include treatment of adults…
Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio (inclisiran) to enable earlier use in patients with elevated LDL-C who…
Read More...
Read More...
Astellas Completes Acquisition of Iveric Bio
Astellas Pharma Inc. announced that it has successfully completed the acquisition of IVERIC bio, Inc. with respect to the announcement on April 30, 2023, through its indirect…
Read More...
Read More...
SK bioscience- Government Pharmaceutical Organization Sign Memorandum of Understanding to Strengthen…
SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that the company has signed a Memorandum of Understanding…
Read More...
Read More...
Astellas Announces FDA Grants Priority Review for Zolbetuximab Biologics License Application
Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company's Biologics License Application (BLA) for…
Read More...
Read More...
Lilly to Acquire Sigilon Therapeutics
Eli Lilly and Company and Sigilon Therapeutics, Inc. announced a definitive agreement for Lilly to acquire Sigilon, a biopharmaceutical company that seeks to develop functional cures…
Read More...
Read More...
GSK completes acquisition of BELLUS Health
GSK plc and BELLUS Health Inc. announced GSK has completed the acquisition of BELLUS, a biopharmaceutical company working to better the lives of patients suffering from refractory…
Read More...
Read More...
Xigduo XR approved in China for adults with type-2 diabetes
AstraZeneca’s Xigduo XR (dapagliflozin and metformin hydrochloride extended-release), a once-daily fixed-dose combination, has been approved by China’s National Medical Products…
Read More...
Read More...
GSK receives US FDA Fast Track designation for investigational vaccine against gonorrhoea
GSK plc announced the US Food and Drug Administration (FDA) has granted a Fast Track designation for its Neisseria gonorrhoeae investigational vaccine (NgG). The vaccine candidate is…
Read More...
Read More...
FDA Accepts Pfizer’s Application for Hemophilia B Gene Therapy Fidanacogene Elaparvovec
Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for fidanacogene elaparvovec for the treatment of…
Read More...
Read More...
FDA approves Jardiance (empagliflozin) for the treatment of type 2 diabetes in children 10 years and…
The U.S. Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) 10 mg and 25 mg tablets to lower blood sugar along with diet and exercise in children 10 years and…
Read More...
Read More...
Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology
Eli Lilly and Company and DICE Therapeutics, Inc. announced a definitive agreement for Lilly to acquire DICE.
DICE is a biopharmaceutical company that leverages its proprietary…
Read More...
Read More...
Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative…
Astellas Pharma Inc. announced a research collaboration and exclusive option agreement to discover multiple innovative protein degraders.
Under the terms of the agreement, the two…
Read More...
Read More...
Soliris approved in China for the treatment of adults with refractory generalised myasthenia gravis
Soliris (eculizumab) has been approved in China for the treatment of adult patients with refractory generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR)…
Read More...
Read More...
INJECTAFER Approved in the U.S. for the Treatment of Iron Deficiency in Adult Patients with Heart…
Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, announced that the U.S. Food and Drug Administration (FDA) approved INJECTAFER (ferric carboxymaltose…
Read More...
Read More...
Bayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical…
Bayer and Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, announced an exclusive license agreement to develop and commercialize Cedilla…
Read More...
Read More...